Royalty Pharma(RPRX) - 2024 Q4 - Earnings Call Presentation

Strong Royalty Receipts growth; Portfolio Receipts growth impacted by a high base of comparison Capital Deployment of $2.8 billion in 2024 with royalties on eight new therapies added to the portfolio Exciting new product launches expected across the royalty portfolio in 2025 • Royalty Pharma to benefit in 2025 from new product launches, including Servier's Voranigo, Bristol Myers Squibb's Cobenfy, Ascendis' Yorvipath, Syndax and Incyte's Niktimvo and Geron's Rytelo. Financial guidance for full year 2025 (ex ...